Vaso Corp (VASO) Stock Price & Analysis

Vaso Corp (VASO) rose 0.00% to USD 0.19 as of June 11, 2026 at 22:18 UTC, according to Nexqual real-time market data.

VASO last closed at USD 0.19; the session ranged USD 0.19–0.19 on volume of 5,000 shares. Market capitalization is $33.44M, with a 52-week range of USD 0.11–0.25 (OQX). Source: Nexqual, June 11, 2026 at 22:18 UTC.

Key Statistics (as of June 11, 2026 at 22:18 UTC)

Technical Analysis (VASO)

Nexqual's technical model rates VASO "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 11, 2026 at 22:18 UTC.

Analyst Ratings (VASO)

Wall Street analysts rate VASO "None", per Nexqual as of June 11, 2026 at 22:18 UTC.

Earnings (VASO)

Source: Nexqual, June 11, 2026 at 22:18 UTC.

Financials & Fundamentals (VASO)

Source: Nexqual, June 11, 2026 at 22:18 UTC.

Financial Health Score (VASO)

Nexqual rates Vaso Corp's overall financial health "Mixed" across five dimensions, as of June 11, 2026 at 22:18 UTC.

Ownership (VASO)

Source: Nexqual, June 11, 2026 at 22:18 UTC.

Leadership (VASO)

Vaso Corp is led by Jun Ma (age 62), President, CEO & Director, per Nexqual as of June 11, 2026 at 22:18 UTC.

From Vaso Corp's Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• We are therefore subject to regulation from the Public Utility Commissions in each state.   Intellectual Property   In addition to other methods of protecting our proprietary technology, know-how and show-how as well as trade secrets, we pursue a policy of seeking patent protection, both in the US and abroad, for our proprietary technologies including those in Biox ® and MobiCare ® products.
• VasoMedical's proprietary devices and software primarily consist of cardiovascular diagnostic and therapeutic applications, including:           This segment uses its substantial in-house knowledge and intellectual property for cardiovascular devices and software coupled with its engineering resources to cost-effectively create and market its proprietary technology.
• These devices and software primarily consist of cardiovascular diagnostic and therapeutic applications, including:           This segment uses its extensive in-house knowledge and intellectual property for cardiovascular devices and software coupled with its engineering resources to cost effectively create and market its proprietary technology.
• We manage and evaluate our operations, and report our financial results, through these three business segments.         The Company's website is www.vasocorporation.com.   1     VasoTechnology (IT Segment)   VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, "NetWolves").

Partnerships

• Concurrently with the closing of the transaction, the Company signed Management Service Agreement with EECP Global to provide management service for the business and operation of EECP Global in the United States.
• In March 2018, the Company terminated the cooperation agreement with PSK and sold its shares in VSK to PSK.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 22:18 UTC. This page is informational and not investment advice.